Gilead surges after report suggests COVID-19 patients responding to remdesivir

(Reuters) - Shares of Gilead Sciences Inc soared 15% on Thursday after a media report suggested that severe COVID-19 patients were positively responding to the drugmaker's experimental treatment remdesivir. A Chicago hospital treating COVID-19 patients with the antiviral medication as part of a trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, according to medical news website STAT..